Alligent Biopharm Consulting (Europe) Limited
Other professional, scientific and technical activities n.e.c. · Horsham
ActiveUnited KingdomIncorporated 2016Private Limited Company
Financial position
Accounts to 2025-12-31 · USD · Company accounts
Net assets
USD 679,275,000
Cash
—
Turnover
USD 2,928,000
Profit / loss
USD 6,041,000
Current assets
—
Creditors < 1 year
USD 35,009,000
Equity
USD 679,275,000
Average employees
0
Balance-sheet trend
USD · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2025-12-31Company · AI-read | 2024-12-31Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | USD 679,275,000 | USD 673,234,000 |
| Equity | USD 679,275,000 | USD 673,234,000 |
| Share capital | USD 262,766,000 | USD 262,766,000 |
| Retained earnings | USD 65,140,000 | USD 59,099,000 |
| Assets | ||
| Fixed assets | USD 651,684,000 | USD 651,697,000 |
| Property, plant & equipment | — | USD 13,000 |
| Investments | USD 651,684,000 | USD 651,684,000 |
| Debtors | USD 62,600,000 | USD 56,743,000 |
| Liabilities | ||
| Creditors within one year | USD 35,009,000 | USD 35,202,000 |
| Creditors after one year | — | USD 1,000 |
| Provisions | — | USD 3,000 |
| Net current assets | USD 27,591,000 | USD 21,541,000 |
| Assets less current liabilities | USD 679,275,000 | USD 673,238,000 |
| Profit & loss | ||
| Turnover | USD 2,928,000 | USD 3,845,000 |
| Cost of sales | USD 2,085,000 | USD 3,190,000 |
| Gross profit | USD 843,000 | USD 655,000 |
| Administrative expenses | USD 499,000 | USD 369,000 |
| Operating profit | USD 344,000 | USD 286,000 |
| Interest receivable | USD 5,694,000 | USD 5,694,000 |
| Profit before tax | USD 6,038,000 | USD 5,980,000 |
| Tax | −USD 3,000 | −USD 3,000 |
| Profit / loss | USD 6,041,000 | USD 5,983,000 |
| Operating costs | ||
| Depreciation | USD 13,000 | USD 17,000 |
| People & pay | ||
| Average employees | 0 | 0 |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2025-12-31 say about themselves, read by AI from the scanned filing.
- Audit
- Subsidiary audit exemption, parent guarantee (s479A)
- Immediate parent
- Envision Pharma US Holdco Inc
- Ultimate parent
- Evidence Topco Limited
- Ultimate controlling party
- GHO Capital Partners LLP
- Accounts
- Medium-sized company · FRS 102
- Approved
- 2026-08-27, signed by S B Rudnick
Share classes (1)
- 26,276,621,170 Ordinary of $0.01
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesShow 4 satisfied / released
All Assets · created 2020-11-10 · satisfied 2026-04-10
—
SatisfiedFixed · created 2020-11-10 · satisfied 2026-04-10
—
SatisfiedAll Assets · created 2020-11-04 · satisfied 2026-04-10
—
SatisfiedAll Assets · created 2016-07-01 · satisfied 2026-04-10
—
Satisfied